Photocure ASA (0IMT) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right, well, good afternoon and good morning. This is Dan Schneider, CEO and President of Photocare. With me today is Eric Dahl, CFO, and welcome to the first quarter 2025 results. Just a reminder, the usual disclaimers are in place for today's presentation. So let's just first start with our strategic priorities and initiatives to make sure everyone's well grounded. We plan on delivering on our financial guidance for growth and revenue and EBITDA this year and continue generating operating income. We are driving the mobile strategy. We'll get into that today and its success so far, and also increasing our penetration, our priority growth markets, and we have some recent developments to talk about there as well, and to continue to expand our geographic footprint and leverage our distribution partnerships. In positioning and access, it's really key here that we don't become the next Kodak film. And by that, I mean we need to remain relevant in the marketplace and strengthen our position as the primary diagnostic for precision diagnostics in bladder cancer care as we see the new emerging non-muscle invasive bladder cancer therapies come to market. In addition, we want to support the continued entrance of high-def blue light machines into the U.S. market and also globally, including Canada and Europe. And we do this through both the pressure we're putting in and on the citizen's petition, as well as alternative ways. And thirdly, our partnership with Richard Wolff in one, the launch of this interim solution for Europe to keep flexible blue light cystoscopy alive, as well as collecting data. And then also, most importantly, advancing the development of a fully optimized high-def system that we intend to launch in the coming years. And then finally, the acquire and tr...